BRISTOL-MYERS SQUIBB COMPANY Estimated Litigation Liability, Current
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Estimated Litigation Liability, Current of $75.00 million as of 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LitigationReserveCurrent · last filed 2019-10-31
- 2019-09-30: Estimated Litigation Liability, Current $75.00M.
- 2019-06-30: Estimated Litigation Liability, Current $80.00M.
- 2019-03-31: Estimated Litigation Liability, Current $79.00M.
- 2018-12-31: Estimated Litigation Liability, Current $118.00M.
| Period end | Estimated Litigation Liability, Current | Estimated Litigation Liability, Current as first filed |
|---|---|---|
| 2019-09-30 | $75.00M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $80.00M 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $79.00M 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $118.00M 10-Q · filed 2019-10-31 | |
| 2018-09-30 | $41.00M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $31.00M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $35.00M 10-Q · filed 2018-04-26 | |
| 2017-12-31 | $38.00M 10-K · filed 2019-02-25 | |
| 2017-09-30 | $35.00M 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $35.00M 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $36.00M 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $43.00M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $123.00M 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $146.00M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $169.00M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $189.00M 10-K · filed 2017-02-21 | |
| 2014-12-31 | $43.00M 10-K · filed 2016-02-12 | |
| 2013-12-31 | $65.00M 10-K · filed 2015-02-13 | |
| 2012-12-31 | $162.00M 10-K · filed 2014-02-14 | |
| 2011-12-31 | $65.00M 10-K · filed 2013-02-15 | $32.00M 10-K · filed 2012-02-17 |
| 2010-12-31 | $54.00M 10-K · filed 2012-02-17 | |
| 2009-09-30 | $174.00M 10-Q · filed 2009-10-22 | |
| 2008-12-31 | $38.00M 10-Q · filed 2009-10-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |